Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.
Bouhuys, Marleen; Lexmond, Willem S.; Dijkstra, Gerardet al.
[en] INTRODUCTION: Anti-tumour necrosis factor (TNF) therapy has greatly improved treatment outcomes in patients with inflammatory bowel disease (IBD), but long-term use is associated with cutaneous reactions, susceptibility to infections and frequent injections or hospital visits. Several non-controlled studies have demonstrated that dose reduction is feasible for a subset of patients, provided that early detection of a disease flare is possible. Here, we aim to compare the effectiveness of interval lengthening with standard dosing in maintaining remission in young patients with IBD. METHODS AND ANALYSIS: In this international, prospective, non-inferiority, partially randomised patient preference trial, we aim to recruit 148 patients aged 12-25 years with luminal Crohn's disease or ulcerative colitis in sustained remission (ie, three consecutive in-range faecal calprotectin (FC) results or recently confirmed endoscopic remission). In the interventional arm, the dosing interval will be lengthened from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users. In the control group, standard dosing will be continued. Rapid tests will be performed for FC every 4 weeks and for anti-TNF trough levels every 12 weeks. The primary outcome is the cumulative incidence of out-of-range FC results at 48-week follow-up. Secondary endpoints include time to get out-of-range FC results, cumulative incidence of adverse effects, proportion of patients progressing to loss of response and identification of predictors of successful interval lengthening. ETHICS AND DISSEMINATION: The protocol has been approved by the Medical Ethics Review Committee of the University Medical Centre Groningen and is pending at the other participating centres. Results will be disseminated in peer-reviewed journals and presented at scientific meetings. TRIAL REGISTRATION NUMBER: EudraCT number: 2020-001811-26; ClinicalTrials.gov Identifier: NCT04646187. Protocol version 4, date 17 September 2021.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Bouhuys, Marleen
Lexmond, Willem S.
Dijkstra, Gerard
Lobatón, Triana
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
van Biervliet, Stephanie
Groen, Henk
Guardiola, Jordi
Rheenen, Patrick Van
Language :
English
Title :
Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.
Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013;7:213-21.
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. J Crohns Colitis 2020;14:4-22.
Ungaro RC, Aggarwal S, Topaloglu O, et al. Systematic review and meta-analysis: Efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42.
van Rheenen H, van Rheenen PF. Long-Term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn's disease: A systematic review of real-world evidence studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121.
Bressler B, Mantzaris G, Silverberg M, et al. P621 real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: Results from the EVOLVE study. J Crohns Colitis 2019;13:S427-8.
Yarur A, Mantzaris G, Silverberg M, et al. P573 real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the evolve study. J Crohns Colitis 2019;13:S400-1.
Denson LA, Curran M, McGovern DPB, et al. Challenges in IBD research: Precision medicine. Inflamm Bowel Dis 2019;25:S31-9.
Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2016;111:632-47.
Doherty G, Katsanos KH, Burisch J, et al. European crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease. J Crohns Colitis 2018;12:17-31.
Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of infliximab maintenance therapy from 8-to 10-week dosing interval based on faecal calprotectin in patients with Crohn's disease. J Crohns Colitis 2016;10:371-2.
Buurman DJ, Maurer JM, Keizer RJ, et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: Potential implications for dosing in clinical practice. Aliment Pharmacol Ther 2015;42:529-39.
Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: Systematic analysis of the literature and meta-analysis. Ann Rheum Dis 2018;77:515-22.
Van Steenbergen S, Bian S, Vermeire S, et al. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease-a nested case-control study. Aliment Pharmacol Ther 2017;45:923-32.
Pouillon L, Lamoureux A, Pineton de Chambrun G, et al. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis 2019;51:236-41.
Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.
Solitano V, D'Amico F, Zacharopoulou E, et al. Early intervention in ulcerative colitis: Ready for prime time J Clin Med 2020;9. doi:10.3390/jcm9082646. [Epub ahead of print: 14 08 2020].
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: Towards disease modification trials. Gut 2017;66:2179-87.
Yzet C, Ungaro R, Bossuyt P, et al. OP35 endoscopic and deep remission at 1 year prevents disease progression in early crohn's disease: Long-term data from CALM. J Crohns Colitis 2019;13:S024-5.
Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38.
Kolho K-L, Sipponen T. The long-term outcome of anti-tumor necrosis factor-therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 2014;49:434-41.
Zubin G, Peter L. Predicting endoscopic crohn's disease activity before and after induction therapy in children: A comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386-91.
Ziv-Baran T, Hussey S, Sladek M, et al. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric crohn's disease. Aliment Pharmacol Ther 2018;48:1242-50.
Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:e5:63-70
Guardiola J, Lobatón T, Cerrillo E, et al. Recommendations of the spanish working group on crohn's disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:514-29.
Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: A systematic review and practical guide. Inflamm Bowel Dis 2017;23:894-902.
Lobatón T, López-Garciá A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in crohn's disease. J Crohns Colitis 2013;7:e641-51.
Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with crohn's disease. Clin Gastroenterol Hepatol 2021;19:1835-1844. e6.
Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034-42.
Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014;12:1865-70.
Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on crohn's disease (calm): A multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779-89.
Kristensen V, Røseth A, Ahmad T. Fecal calprotectin: A reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract 2017;2017:2098293-5.
Jauregui-Amezaga A, López-Cerón M, Aceituno M, et al. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: A prospective study. Inflamm Bowel Dis 2014;20:1187-93.
Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther 2016;44:495-504.
European Medicines Agency. Remicade 100 mg powder for concentrate for solution for infusion-summary of product characteristics (SPC)-(eMC), 2009. Available: Https://www.ema. europa. eu/en/documents/product-information/remicade-eparproduct-information_en.pdf [Accessed 31 Mar 2020].
European Medicines Agency. Humira 20 mg solution for injection in pre-filled syringe-summary of product characteristics (SPC)-(eMC), 2008. Available: Https://www.ema. europa. eu/en/documents/productinformation/humira-epar-product-information_en.pdf [Accessed 31 Mar 2020].
Shivaji UN, Sharratt CL, Thomas T, et al. Review article: Managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.
Reeve E, Low L-F, Shakib S, et al. Development and validation of the revised patients' attitudes towards deprescribing (rPATD) questionnaire: Versions for older adults and caregivers. Drugs Aging 2016;33:913-28.
Edelman M, Jellema P, Hak E, et al. Patients' attitudes towards deprescribing alpha-blockers and their willingness to participate in a discontinuation trial. Drugs Aging 2019;36:1133-9.
Roux B, Sirois C, Niquille A, et al. Cross-cultural adaptation and psychometric validation of the revised patients' attitudes towards deprescribing (rPATD) questionnaire in French. Res Social Adm Pharm 2021;17:1453-62.
de Juan Roldán J, Gavilán Moral E, Garciá Ruiz A. Estudio de validación al castellano del cuestionario revised patients' attitudes towards deprescribing (rPATD) para evaluar las actitudes de los pacientes hacia la deprescripción. Barcelona: XXXVIII Congreso semFYC, 2018.
Heida A, Knol M, Kobold AM, et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol 2017;15:1742-9.
Haisma S-M, Galaurchi A, Almahwzi S, et al. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One 2019;14:e0214751.
Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007;133:423-32.
Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660-6.
Hart AL, Lomer M, Verjee A, et al. What are the top 10 research questions in the treatment of inflammatory bowel disease A priority setting partnership with the James Lind alliance. J Crohns Colitis 2017;11:204-11.
Geldof J, LeBlanc J-F, Lucaciu L, et al. Are we addressing the top 10 research priorities in IBD Frontline Gastroenterol 2020;2:flgastro-2020-101579.
Schultz KF, GD A. Boosting recruitment to randomised controlled trials. In: Essential concepts in clinical research. 2nd edn. Edinburgh: Elsevier limited, 2019: 112-3.
Rush AJ. STAR D: What have we learned Am J Psychiatry 2007;164:201-4.
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Jama 2013;310:2191-4.
